{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:32:44Z","timestamp":1786120364909,"version":"build-2736575974"},"reference-count":18,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2011,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>The frequency of ocular myasthenia gravis (OMG) in patients referred to an academic neuro-ophthalmology clinic for suspected myasthenia gravis is not known. Our objective was to determine the frequency of ocular OMG in patients referred to an academic neuro-ophthalmologist and determine alternate diagnoses and response to therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>We performed a retrospective chart review of patients presenting to the University of Kansas Neuro-Ophthalmology Clinic with suspected OMG over 9 years. We defined OMG as isolated ptosis\/diplopia at initial presentation supported by at least one of the following abnormal tests: edrophonium test, ice test, Cogan lid twitch, fatigability on sustained upgaze, acetylcholine receptor binding antibody, greater than 10% decrement on repetitive stimulation, or abnormal single-fiber jitter. We also determined the cause of ptosis\/diplopia if it was not the result of OMG. Patients who progressed from OMG to generalized disease were termed transformed myasthenia gravis (TMG).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>One hundred thirty-eight patients were referred with mean age at presentation 58 \u00b1 19 years. Myasthenia gravis was diagnosed in 101 patients; 95 had OMG; six had generalized MG. Diagnosis in the other 37 was cranial nerve palsies (nine), levator dehiscence (five), multiple sclerosis (two), blepharospasm (two), decompensated phorias (three), accommodation spasm (four), exophoria (three), skew deviation (two), Graves disease (one), hypertropia (one), myopathy (one), neurosarcoidosis (one), progressive supranuclear palsy (one), Miller Fisher variant of Guillain-Barre syndrome (one), and obstructive sleep apnea (one). Mean follow-up was 3.0 \u00b1 2.8 years. Test sensitivity\/specificity in OMG was fatigability on sustained upgaze 0.80\/0.63; ice pack 0.80\/0.25; Cogan lid twitch 0.59\/1.00; edrophonium 0.88\/0.50; acetylcholine receptor binding antibody 0.38\/1.00; repetitive nerve stimulation 0.24\/1.00; and single-fiber electromyography 0.90\/1.00. Pyridostigmine was used without prednisone in 59 of 97 patients with OMG and 12 of 59 developed TMG. Prednisone was used in 38 patients; 21 of 38 (55%) met Myasthenia Gravis Foundation of America improvement status and none had TMG.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>The diagnosis of myasthenia gravis was confirmed in the majority of patients referred to our academic neuro-ophthalmology clinic, but 27% did not have myasthenia gravis. It is possible that prednisone treatment of OMG may prevent progression to TMG, but further study is required.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/cnd.0b013e31821c5634","type":"journal-article","created":{"date-parts":[[2011,10,4]],"date-time":"2011-10-04T15:51:21Z","timestamp":1317743481000},"page":"46-52","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":55,"title":["Ocular Myasthenia Gravis in an Academic Neuro-Ophthalmology Clinic: Clinical Features and Therapeutic Response"],"prefix":"10.1097","volume":"13","author":[{"given":"Manoj Kumar","family":"Mittal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard J","family":"Barohn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mamatha","family":"Pasnoor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"April","family":"McVey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Herbelin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Whittaker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mazen","family":"Dimachkie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-5-20240808","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.jns.2007.02.020","article-title":"A prospective study assessing the utility of Cogans lid twitch sign in patients with isolated unilateral or bilateral ptosis.","volume":"256","author":"Van Stavern","year":"2007","journal-title":"J Neurol Sci"},{"key":"R2-5-20240808","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1196\/annals.1254.056","article-title":"Standards of measurements in myasthenia gravis.","volume":"998","author":"Barohn","year":"2003","journal-title":"Ann N Y Acad Sci"},{"key":"R3-5-20240808","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.jns.2003.08.017","article-title":"The effect of prednisone on the progression from ocular to generalized myasthenia gravis.","volume":"217","author":"Monsul","year":"2004","journal-title":"J Neurol Sci"},{"key":"R4-5-20240808","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1001\/archneur.60.10.1491-b","article-title":"Development of generalized myasthenia gravis in patients with ocular myasthenia gravis.","volume":"60","author":"Papapetropoulos","year":"2003","journal-title":"Arch Neurol"},{"key":"R5-5-20240808","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1097\/00041327-200312000-00002","article-title":"Immunotherapy of ocular myasthenia gravis reduces conversion to generalized myasthenia gravis.","volume":"23","author":"Mee","year":"2003","journal-title":"J Neuroophthalmol"},{"key":"R6-5-20240808","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1001\/archneur.60.2.243","article-title":"Development of generalized disease at 2 years in patients with ocular myasthenia gravis.","volume":"60","author":"Kupersmith","year":"2003","journal-title":"Arch Neurol"},{"key":"R7-5-20240808","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1136\/jnnp.62.2.156","article-title":"Ocular myasthenia gravis: response to long-term immunosuppressive treatment.","volume":"62","author":"Sommer","year":"1997","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R8-5-20240808","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1111\/j.1749-6632.1987.tb51317.x","article-title":"The course of myasthenia gravis and therapies affecting outcome.","volume":"505","author":"Grob","year":"1987","journal-title":"Ann N Y Acad Sci"},{"key":"R9-5-20240808","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1097\/WCO.0b013e3282f4098e","article-title":"Ocular myasthenia: diagnostic and treatment recommendations and the evidence base.","volume":"21","author":"Luchanok","year":"2008","journal-title":"Curr Opin Neurol"},{"key":"R10-5-20240808","first-page":"45","article-title":"Comparison of diagnostic tests in myasthenia gravis.","volume":"19","author":"Nicholson","year":"1983","journal-title":"Clin Exp Neurol"},{"key":"R11-5-20240808","doi-asserted-by":"crossref","first-page":"2236","DOI":"10.1016\/j.ophtha.2009.04.039","article-title":"The ice pack test in the differential diagnosis of myasthenic diplopia.","volume":"116","author":"Chatzistefanou","year":"2009","journal-title":"Ophthalmology"},{"key":"R12-5-20240808","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1007\/s00415-009-5120-8","article-title":"Ocular myasthenia gravis: treatment successes and failures in patients with long-term follow-up.","volume":"256","author":"Kupersmith","year":"2009","journal-title":"J Neurol"},{"key":"R13-5-20240808","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1212\/01.wnl.0000263481.14289.90","article-title":"Evidence report: the medical treatment of ocular myasthenia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology.","volume":"68","author":"Benatar","year":"2007","journal-title":"Neurology"},{"key":"R14-5-20240808","first-page":"CD005081","article-title":"Medical and surgical treatment for ocular myasthenia.","volume":"2","author":"Benatar","year":"2006","journal-title":"Cochrane Database Syst Rev"},{"key":"R15-5-20240808","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1136\/bjo.2004.063404","article-title":"Ocular motor dysfunction and ptosis in ocular myasthenia gravis: effects of treatment.","volume":"89","author":"Kupersmith","year":"2005","journal-title":"Br J Ophthalmol"},{"key":"R16-5-20240808","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1097\/00041327-200312000-00001","article-title":"Does early immunotherapy reduce the conversion of ocular myasthenia gravis to generalized myasthenia gravis?","volume":"23","author":"Kupersmith","year":"2003","journal-title":"J Neuroophthalmol"},{"key":"R17-5-20240808","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.nmd.2006.05.006","article-title":"A systematic review of diagnostic studies in myasthenia gravis.","volume":"16","author":"Benatar","year":"2006","journal-title":"Neuromuscul Disord"},{"key":"R18-5-20240808","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/S1388-2457(00)00307-2","article-title":"SFEMG in ocular myasthenia gravis diagnosis.","volume":"111","author":"Padua","year":"2000","journal-title":"Clin Neurophysiol"}],"container-title":["Journal of Clinical Neuromuscular Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00131402-201109000-00005","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T20:27:00Z","timestamp":1786048020000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00131402-201109000-00005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,9]]},"references-count":18,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011]]}},"URL":"https:\/\/doi.org\/10.1097\/cnd.0b013e31821c5634","relation":{},"ISSN":["1522-0443"],"issn-type":[{"value":"1522-0443","type":"print"}],"subject":[],"published":{"date-parts":[[2011,9]]}}}